- Respiratory Syncytial Virus (RSV) infection represents a major public health concern, particularly among infants, young children, and elderly adults, due to its potential to cause severe respiratory illness, including bronchiolitis and pneumonia. The virus’s seasonal nature and high hospitalization rates among vulnerable populations are making RSV a critical target for prevention and treatment strategies in the global healthcare landscape.
- The rising demand for effective RSV therapeutics is primarily driven by increasing RSV incidence worldwide, heightened clinical awareness, and the growing availability of advanced diagnostics and care options, such as point-of-care swab tests and pulse oximetry monitoring.
- North America dominates the RSV infection market with the largest revenue share of 37.8% in 2025, supported by a well-established healthcare infrastructure, strong reimbursement environment, and proactive vaccine development efforts. The U.S., in particular, is witnessing significant investment in monoclonal antibody therapies and maternal immunization programs, which is expected to expand further as more RSV vaccines and treatments receive regulatory approvals.
- Asia-Pacific is anticipated to be the fastest-growing region in the RSV infection market during the forecast period, owing to rising birth rates, improved access to diagnostics, and increased healthcare spending in emerging economies such as India and China. Additionally, government-led infant immunization campaigns and awareness programs are contributing to higher RSV diagnosis and treatment uptake.
- Among treatment modalities, supportive care dominates the market with a revenue share of 58.3% in 2025, owing to its foundational role in managing RSV symptoms such as oxygen therapy, hydration, and fever control. However, the demand for advanced antiviral therapies and monoclonal antibodies is increasing rapidly, especially in high-risk patient groups, which will reshape the market landscape in the years ahead.
